The latest article on the Healthy minds lab study on how fluvoxamine can help treat and prevent sever COVID-19 symptoms.
Category: Covid-19
Investigating Antidepressants’ Surprising Effect on COVID Deaths (Links to an external site)
Another article describing Andrea Fekete and Eric Lenses findings on fluvoxamine’s efficacy against fighting the worst of the COVID symptoms. The article describes the way fluvoxamine allows for the body’s inflammatory system to keep in check due to the presence of the sigma-1 receptor.
Cheap, generic anti-depressant may reduce severe Covid-19 disease, study finds (Links to an external site)
CNN’s discussion on the latest study that found that fluvoxamine could reduce the risk of having severe COVID-19 symptoms. “Fluvoxamine may reduce the production of inflammatory molecules called cytokines that can be triggered by SARS-COV-2 infection.”
A cheap antidepressant lowers the risk of COVID hospitalization, a large study finds. (Links to an external site)
Effect of early treatment with fluvoxamine on risk of hospitalization among patients with COVID (Links to an external site)
This is the first large and randomized controlled trial test to test the efficacy of fluvoxamine for acute treatment of COVID-19. In the study, they found an absolute risk reduction of 5.0% and a 32% RR reduction.
Update on our study of an early treatment COVID-19
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19 A Randomized Clinical Trial Eric J. Lenze, MD1; Caline Mattar, MD2; Charles F. Zorumski, MD1; Angela Stevens, BA1; Julie Schweiger1; Ginger E. Nicol, MD1; J. Philip Miller, AB3; Lei Yang, MPH, MSIS1; Michael Yingling, MS1; Michael S. Avidan, MBBCh4; Angela M. Reiersen, MD, MPE1JAMA. Published online November 12, 2020. doi:10.1001/jama.2020.22760
Study to evaluate antidepressants as potential COVID-19 treatment (Links to an external site)
